Concord Biotech Ltd. benchmarking: Perfomance to industry peers

Financial

	Concord Biotech	Biocon	Guj. Themis Biosyn
Operational Metrics
Pharmaceuticals
Global DMFs filed	135.0 .	n/a	n/a
US DMF Filings	20.0 .	n/a	n/a
Europe DMF Filings	65.0 .	n/a	n/a
Fermentation Capacity	1250.0 KL	125.0 KL	n/a
Total reactor capacity	1250.0 kL	n/a	n/a
Japan DMF Filings	4.0 .	n/a	n/a
R&D as a % of Total Sales	2.3 %	7.0 %	n/a
Financials
5 yr Average ROE	19.73 %	5.97 %	34.65 %
5yr average Equity Multiplier	1.21	2.64	1.29
5yr Average Asset Turnover Ratio	0.54	0.31	0.74
5yr Avg Net Profit Margin	30.4 %	7.2 %	35.51 %
Price to Book	8.58	2.05	18.42
P/E	48.42	113.18	100.85
5yr Avg Cash Conversion Cycle	76.63 Days	-193.26 Days	-112.39 Days
Inventory Days	79.03 Days	102.53 Days	22.82 Days
Days Receivable	132.49 Days	139.43 Days	70.51 Days
Days Payable	157.9 Days	307.82 Days	130.88 Days
5yr Average Interest Coverage Ratio	195.92	8.77	216.76
5yr Avg ROCE	25.76 %	6.71 %	45.66 %
5yr Avg Operating Profit Margin	43.43 %	19.38 %	47.34 %
5 yr average Debt to Equity	0.03	0.75	0.03
5yr CAGR Net Profit	9.62 %	6.47 %	10.07 %
5yr Average Return on Assets	16.36 %	2.35 %	26.69 %
Shareholdings
Promoter Holding	44.08 %	54.45 %	70.86 %
Share Pledged by Promoters	0.0	0.0	3.3 %
Change in Promoter Holding (3 Yrs)	0.0	-6.19 %	-4.13 %
Change in Mutual Fund Holding (3 Yrs)	-1.05 %	10.92 %	1.14 %

	Concord Biotech	Biocon	Guj. Themis Biosyn
Product Wise Break-Up	Product Wise Break-Up API - Fermentation based 75.39 Formulations 24.61 Generics 0 Novel 0 Biosimilars 0 Syngene (Research Services) 0 Branded Formulations 0 Biologics 0 0	Product Wise Break-Up Biosimilars 61.01 Novel 0 API - Fermentation based 0 0 Generics 17.29 Biologics 0 Syngene (Research Services) 21.71 Formulations 0 Branded Formulations 0	Product Wise Break-Up Biosimilars 0 Novel 0 API - Fermentation based 0 Pharmaceutical 100.0 Generics 0 Biologics 0 Syngene (Research Services) 0 Formulations 0 Branded Formulations 0
Location Wise Break-Up	Location Wise Break-Up India 59.31 Rest of the World 40.69 USA 0 Ireland 0	Location Wise Break-Up Rest of the World 22.24 India 6.4 USA 46.14 Ireland 25.21 Others 0.01	-
Asset Break-Up	Asset Break-Up India 99.92 Novel Biologics 0 Research 0 Biosimilars 0 Generics 0 Others 0.08	Asset Break-Up Biosimilars 75.35 India 0 Research 11.25 Novel Biologics 0 Generics 13.4	-